The approved dose is 300 mg by subcutaneous injection every four weeks. "The EU approval of Xolair in CSU is truly exciting for patients with this chronic and debilitating skin disease," said ...

Xolair (omalizumab) is a prescription drug that works by blocking IgE to help reduce inflammation. Your response to this drug may vary based on your medical history and diagnosis. IgE is a protein ...